Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or “lot” of Intravenous Immunoglobulin.
North America region is the largest supplier of intravenous immunoglobulin (IVIg), with a production market share nearly 48% in 2016. Europe is the second largest supplier of intravenous immunoglobulin (IVIg), enjoying production market share nearly 23% in 2016.
North America is the largest sales place, with a sales market share nearly 44% in 2016. Following North America, Europe is the second largest sales place with the sales market share of 22%.
Market competition is intense. Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Intravenous Immunoglobulin (IVIg) market is valued at 8120 million US$ in 2018 and will reach 12800 million US$ by the end of 2025, growing at a CAGR of 5.9% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intravenous Immunoglobulin (IVIg) market based on company, product type, end user and key regions.
This report studies the global market size of Intravenous Immunoglobulin (IVIg) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Intravenous Immunoglobulin (IVIg) in these regions.
This research report categorizes the global Intravenous Immunoglobulin (IVIg) market by top players/brands, region, type and end user. This report also studies the global Intravenous Immunoglobulin (IVIg) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sichuan Yuanda Shuyang
Market size by Product
Market size by End User
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global Intravenous Immunoglobulin (IVIg) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Intravenous Immunoglobulin (IVIg) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Intravenous Immunoglobulin (IVIg) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Intravenous Immunoglobulin (IVIg) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Intravenous Immunoglobulin (IVIg) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Bottle). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Intravenous Immunoglobulin (IVIg) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.